GILD241115C50000
- 35.20
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences Initiated at Outperform by Wolfe Research
Wolfe Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $110
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Gets a Buy From TD Cowen
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $125
Raymond James Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $103
Gilead Sciences Is Maintained at Hold by Truist Securities
Gilead Sciences Analyst Ratings
Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $95 to $105
Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Gilead Sciences Price Target Raised to $95.00/Share From $84.00 by Barclays
Cantor Fitzgerald Sticks to Its Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $95 to $105
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $80 From $70, Maintains Neutral Rating
Gilead Sciences: Strong Financial Performance and Growth Potential Drive Buy Rating
Barclays Remains a Hold on Gilead Sciences (GILD)